Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease

BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in patients with nonalcoholic fatty liver disease (NAFLD). Weight loss is a key factor for successful NAFLD and CVD therapy. Ursodeoxycholic acid (UDCA), which is one of the first-line therapeutic agents for...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:World J Gastroenterol
Päätekijät: Nadinskaia, Maria, Maevskaya, Marina, Ivashkin, Vladimir, Kodzoeva, Khava, Pirogova, Irina, Chesnokov, Evgeny, Nersesov, Alexander, Kaibullayeva, Jamilya, Konysbekova, Akzhan, Raissova, Aigul, Khamrabaeva, Feruza, Zueva, Elena
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Baishideng Publishing Group Inc 2021
Aiheet:
Clinical Trials Study
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7968130/
https://ncbi.nlm.nih.gov/pubmed/33776366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v27.i10.959
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia